FINWIRES · TerminalLIVE
FINWIRES

$RPRX

6 stories mentioning RPRXUpdated 5d ago

Every FINWIRES story that references RPRX, newest first.

What's the latest news on RPRX?

Wire

Royalty Pharma Shares Fall After Novartis' Pelacarsen Fails Trial

Royalty Pharma (RPRX) shares fell nearly 6% in Tuesday trading after Novartis' (NVS) experimental heart drug pelacarsen failed in a late-stage trial last week, a study in which Royalty Pharma had an indirect financial interest.Novartis' Phase III Lp(a)HORIZON trial of pelacarsen, developed with Ionis Pharmaceuticals, did not meet its primary endpoint of reducing the risk of cardiovascular events compared with placebo, according to a statement released late Friday.Royalty Pharma entered a $500 million funding agreement with Ionis in 2023 that gives it rights to future royalties from Spinraza and pelacarsen.Despite the pelacarsen failure, Royalty Pharma expects to recoup its total investment and make a modest positive return, the company said Friday.Price: $60.48, Change: $-3.48, Percent Change: -5.44%

$NVS$RPRX
Sectors

Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday

Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) marginally advancing.Repligen (RGEN) has agreed to acquire BioLife Solutions (BLFS) in a deal valued at $1.5 billion, the companies said. Shares of Repligen were down more than 4% and BioLife Solutions stock was up more than 2% pre-bell.Royalty Pharma (RPRX) said it will pay up to $425 million, including a $125 million upfront payment, to Neurimmune for a 3% to 4% royalty on worldwide net sales of its interest in AstraZeneca's (AZN) cliramitug. Royalty Pharma stock was down more than 1% pre-bell.Healthcare Services Group (HCSG) shares were 0.8% higher after the company reported that it swung to a Q2 net income as revenue increased during the period.

$AZN$BLFS$HCSG$IBB$RGEN$RPRX$XLV
Insider Trading

Royalty Pharma Insider Sold Shares Worth $8,159,277, According to a Recent SEC Filing

Christopher Hite, Executive Vice President & Chairman, Partnering, on June 23, 2026, sold 150,000 shares in Royalty Pharma (RPRX) for $8,159,277. Following the Form 4 filing with the SEC, Hite has control over a total of 629,399 Class A ordinary shares of the company, with 70,000 shares held directly and 559,399 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802768/000181423826000009/xslF345X05/wk-form4_1782421910.xml

$RPRX
Insider Trading

Royalty Pharma Insider Sold Shares Worth $502,067, According to a Recent SEC Filing

Marshall Urist, Executive Vice President, Research & Investments, on June 24, 2026, sold 9,098 shares in Royalty Pharma (RPRX) for $502,067. Following the Form 4 filing with the SEC, Urist has control over a total of 9,099 Class A ordinary shares of the company, with 9,099 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802768/000183813926000020/xslF345X05/wk-form4_1782422032.xml

$RPRX
Insider Trading

Royalty Pharma Insider Sold Shares Worth $3,476,116, According to a Recent SEC Filing

Terrance P. Coyne, Executive Vice President & CFO, on May 26, 2026, sold 64,399 shares in Royalty Pharma (RPRX) for $3,476,116. Following the Form 4 filing with the SEC, Coyne has control over a total of 50,390 Class A ordinary shares of the company, with 1,500 shares held directly and 48,890 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802768/000181487626000022/xslF345X05/wk-form4_1780001297.xml

$RPRX
Insider Trading

Royalty Pharma Insider Sold Shares Worth $1,731,840, According to a Recent SEC Filing

Terrance P. Coyne, Executive Vice President & CFO, on April 28, 2026, sold 34,791 shares in Royalty Pharma (RPRX) for $1,731,840. Following the Form 4 filing with the SEC, Coyne has control over a total of 90,526 Class A ordinary shares of the company, with 1,500 shares held directly and 89,026 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802768/000181487626000018/xslF345X05/wk-form4_1777586044.xml

$RPRX

Track with the FINWIRES app suite

FolioX
FolioX
Track RPRX in your portfolio
WheelAI
WheelAI
Analyze RPRX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on RPRX